Abstract Body

HPTN 067/ADAPT evaluated tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) regimens for pre-exposure prophylaxis (PrEP). HIV-uninfected women (South Africa) and men who have sex with men (Thailand, US) received 5 weekly observed doses of TDF/FTC (DOT), and were then randomized to a daily, time-driven (twice weekly + post-sex dose), or event-driven (before and after sex) TDF/FTC regimen. We analyzed data from subjects who seroconverted in the study.

Two HIV rapid tests were performed at each visit; infections were confirmed with an HIV RNA assay. Samples were analyzed retrospectively at the HPTN Laboratory Center using two 4th generation assays; a qualitative HIV RNA assay; a viral load assay; Western blot; an HIV-1/HIV-2 discriminatory assay; HIV genotyping; next generation sequencing (NGS); and antiretroviral drug (ARV) testing.

Twelve subjects acquired HIV infection. In 4 cases, at least 1 rapid test was non-reactive at the seroconversion visit. Six subjects were not randomized (3 had acute infection at enrollment, 2 were infected during the DOT phase, 1 was not randomized due to pregnancy and was infected months later). One subject had acute infection at the end of the DOT phase but was not diagnosed for 3-4 months after randomization because HIV rapid tests were non-reactive; resistance testing failed in this case because HIV RNA levels were persistently low/undetectable. Five subjects were infected after randomization. In 4 cases, ARV test results were consistent with infrequent drug use (event-driven arm) or poor adherence (daily or time-driven arm); one woman in the time-driven arm had ARV levels prior to infection indicating PrEP use with 4+ doses/week. She developed HIV resistance consistent with TDF/FTC use (K65R + M184I). Mutations associated with TDF/FTC use were also detected after 4 weekly DOT doses in two subjects who had acute infection at enrollment (one K65R; one M184I). In 2/3 cases, resistance was only detected using NGS.

All but one infection in this study was acquired when subjects were not on PrEP, were in the once-weekly DOT phase, or had ARV levels indicating infrequent dosing. Early infections were often missed by HIV rapid testing, but were detected using a sensitive HIV RNA assay and 4th generation tests. One subject who continued PrEP with undiagnosed infection had persistent low/undetectable HIV RNA. Resistance was detected in 2 subjects who received only 1 TDF/FTC dose/week.